Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination
NCT04403139Phase 4Active, not recruiting
- Sponsor
- University of Washington
- Start
- Apr 2022
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of Zoster vaccine recombinant in varicella zoster virus infection, sponsored by University of Washington. Started Apr 2022; status: active, not recruiting.
02
Drugs
Zoster vaccine recombinant
03
Conditions
varicella zoster virus infection
Beyond the preview
Go deeper on NCT04403139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04403139.